And out of the woodwork come the bulletin board companies:
Press Release
Source: Advanced Viral Research Corp.
ADVR CEO Hirschman Comments on SARS on ABC World News Tonight
Friday April 11, 8:35 am ET
YONKERS, N.Y., April 11 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) today said that Company President and CEO, Shalom Z. Hirschman, M.D., was interviewed by ABC World News Tonight for a segment regarding the search for a treatment for Severe Acute Respiratory Syndrome (SARS), that was broadcast on Thursday, April 10. In the interview, Dr. Hirschman told ABC News, "If in fact a SARS pandemic is developing, that will add urgency to research all over the world."ABC News noted that the National Institute of Allergy and Infectious Diseases is seeking to test more than 2,000 drugs against the SARS virus. ADVR, therefore, could seek an opportunity to offer Product R for consideration to the global scientific community. The full text of the ABC News story is available on www.abcnews.com.
"Product R, a second-generation drug, now being investigated for various uses, is derived from the older drug Reticulose, which was for years listed in the Physicians' Desk Reference (PDR) to treat influenza, mumps and measles and was used by the U.S. Armed Forces to treat viral infections with no reported side effects," noted Dr. Hirschman. "Product R, a novel Peptide Nucleic Acid, which to date has shown no indication of human toxicity, is an immunomodulator that appears to stimulate the pro-inflammatory responses required to combat viral infections such as AIDS and human papilloma virus. With its broad anti- viral activity, no apparent safety issues and the apparent development of a global health emergency, we believe that there is limited risk for health experts to consider the possible use of Product R for the treatment of patients with SARS."
"With the growing number of SARS cases worldwide, and the efforts by the world's leading scientists to find an effective treatment, it is our responsibility to share information about Product R to help the world's scientific community address a possible global epidemic," said Eli Wilner, Chairman of the Board.
The Company noted that three clinical trials of Product R in Israel are currently underway. The Israeli clinical trials for Product R include:
-- a Phase I/II clinical trial with injectable Product R in cachectic
AIDS patients who have failed highly active antiretroviral therapy
(HAART) and require salvage therapy;
-- a Phase I clinical study for the treatment of body wasting (cachexia)
in patients with solid tumors; and
-- a Phase I clinical trial for cachectic patients with hematopoietic and
lymphoid tumors, including acute lymphocytic leukemia, multiple
myeloma, Hodgkin's disease and non-Hodgkin's lymphoma.
Last month, ADVR announced that it had initiated activities necessary to expand the ongoing Israeli clinical trial of Product R for the treatment of AIDS patients on highly active antiretroviral therapy (HAART). ADVR has directed the staff of the Selikoff Center in Israel, in collaboration with the principal investigator, to begin developing protocols for a multi-center, blinded, controlled late stage Phase II clinical trial of Product R in AIDS patients who are in need of salvage therapy.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.
For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.
Sigh.
Peter |
